NASDAQ: OKYOOkyo Pharma Ltd Stock
$1.17-0.05 (-4.1%)
Updated Apr 21, 2025
OKYO Price
$1.17
Fair Value Price
$0.03
Market Cap
$39.71M
52 Week Low
$0.81
52 Week High
$1.74
P/E
-3.08x
P/B
-5.5x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$10.69M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
-1.39
Operating Cash Flow
-$3M
Beta
0.47
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
OKYO Overview
OKYO Pharma Limited, a preclinical biopharmaceutical company, engages in developing therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. Its lead product includes OK-101 for the treatment of dry eye disease. The company is also developing OK-201, a bovine adrenal medulla, lipidated-peptide preclinical analogue candidate for the treatment of neuropathic ocular pain. OKYO Pharma Limited was incorporated in 2007 and is headquartered in London, the United Kingdom.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine OKYO's potential to beat the market
- OKYO doesn't meet the minimum data requirements for our proprietary Zen Ratings model. Learn more about Zen Ratings.
Zen Rating Component Grades
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
OKYO
RankedUnranked of 462
RankedUnranked of 462
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $2.55 | A | |
| $7.66 | A | |
| $22.02 | A |
Be the first to know about important OKYO news, forecast changes, insider trades & much more!
OKYO News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how OKYO scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
OKYO ($1.17) is overvalued by 4,052.17% relative to our estimate of its Fair Value price of $0.03 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
OKYO ($1.17) is not significantly undervalued (4,052.17%) relative to our estimate of its Fair Value price of $0.03 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
OKYO is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more OKYO due diligence checks available for Premium users.
Valuation
OKYO fair value
Fair Value of OKYO stock based on Discounted Cash Flow (DCF)
Price
$1.17
Fair Value
$0.03
Overvalued by
4,052.17%
OKYO ($1.17) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
OKYO ($1.17) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
OKYO is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
OKYO price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-3.08x
Industry
-184.27x
Market
27.14x
OKYO price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
-5.5x
Industry
4.04x
OKYO's financial health
Profit margin
Revenue
$0.0
Net Income
$0.0
Profit Margin
0%
OKYO's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$2.8M
Liabilities
$10.1M
Debt to equity
-1.39
OKYO's short-term liabilities ($10.05M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
OKYO's short-term assets ($2.83M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
OKYO's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
OKYO's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
N/A
Investing
N/A
Financing
N/A
OKYO's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
OKYO vs Biotech Stocks
Okyo Pharma Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.